New Novartis data at ASN Kidney Week and AHA Scientific Sessions demonstrate momentum of broad CRM portfolio and pipeline

Basel, November 4, 2025 – Novartis will present new data from 33 abstracts across its Cardiovascular, Renal, and Metabolic (CRM) disease portfolio at the upcoming American Society of Nephrology (ASN) Kidney Week 2025 in Houston, Texas and American Heart Association's (AHA) Scientific Sessions 2025 in New Orleans, Louisiana, advancing scientific insight into these critical disease areas.

“Novartis will present a broad range of data at ASN and AHA demonstrating innovation and commitment to advancing therapies that address root causes of heart and kidney conditions,” said Ruchira Glaser, M.D., Global Head, Cardiovascular, Renal and Metabolic Development Unit, Novartis. "Studies on both our approved and investigational therapies in these closely connected therapeutic areas reflect our longstanding dedication to deliver meaningful solutions for patients living with some of the rarest to most prevalent CRM diseases worldwide.”

Key highlights of data accepted by ASN include: